食管癌的三维适形放疗同步化疗的临床疗效分析
|
摘要
目的观察三维适形放疗(3DCRT)同步化疗用于食管癌(Esophageal Cancer,简称EC)的成效。方法选2015年4月至2016年8月60例EC患者,等分为甲组(3DCRT治疗组)与乙组(3DCRT~+化疗组)各30例,比较两组疗效。结果乙组近期有效率为86.7%,较高于甲组70.0%(P<0.05);随访1年、2年时,乙组生存率为83.3%、60.0%,高于甲组56.7%、33.3%,乙组术后健康调查简表(SF-36)各维度评分也高于甲组,差异均有统计学意义(P<0.05)。结论 3DCRT联合化疗治疗EC,疗效较为理想,能优化生活质量,值得推广。
Objective To observe the effect of three dimensional conformal radiotherapy(3 DCRT) concurrent chemotherapy on esophageal cancer(EC). Methods 60 patients with EC from April 2015 to August 2016 were divided into group A(3 DCRT treatment group) and group B(3 DCRT + chemotherapy group) with 30 cases in each group.Results The short-term effective rate of group B was 86.7%, higher than 70.0% of group A(< 0.05); the survival rate of group B was 83.3%, 60.0%, higher than 56.7% and 33.3% of group A at 1 and 2 years of follow-up, and the scores of each dimension of SF-36 in group B were also higher than those in group A(< 0.05). Conclusion 3 DCRT combined with chemotherapy is effective in the treatment of EC. It can optimize the quality of life and is worthy of promotion.
Objective To observe the effect of three dimensional conformal radiotherapy(3 DCRT) concurrent chemotherapy on esophageal cancer(EC). Methods 60 patients with EC from April 2015 to August 2016 were divided into group A(3 DCRT treatment group) and group B(3 DCRT + chemotherapy group) with 30 cases in each group.Results The short-term effective rate of group B was 86.7%, higher than 70.0% of group A(< 0.05); the survival rate of group B was 83.3%, 60.0%, higher than 56.7% and 33.3% of group A at 1 and 2 years of follow-up, and the scores of each dimension of SF-36 in group B were also higher than those in group A(< 0.05). Conclusion 3 DCRT combined with chemotherapy is effective in the treatment of EC. It can optimize the quality of life and is worthy of promotion.
引文
[1]丁金泉,张群责,李美丽,等.中晚期老龄食管癌患者应用替吉奥辅以调强放疗的临床研究[J].中国现代医生,2015,53(17):61-63.
[2]张德智,王璐瑶,梁怀虹.中晚期食管癌患者3D-CRT同步化疗的临床效果[J].中国实用医药,2017,12(03):25-27.
[3]沈文斌,高红梅,祝淑钗,等.95例伴气管食管沟淋巴结转移食管癌三维放疗±化疗疗效分析[J].中华放射肿瘤学杂志,2015,24(1):36-40.
[4]张彬,乔田奎,高彩霞,等.同期适形放疗联合化疗治疗中晚期食管癌的临床研究[J].中国癌症杂志,2011,21(10):803-806.
[5]姜威.三维适形放疗同步化疗治疗中晚期食管癌的疗效评价[J].中国继续医学教育,2016,8(19):104-106.
[6]赵维勇,张丽珍,王继荣,等.三维适形放疗联合不同化疗方案治疗中晚期食管癌的临床研究[J].现代肿瘤医学,2012,20(5):956-958.
[7] WelshJ,Settle SH,AminiA,et al.Failure pattems in patients with esophageal cancer treated with definitive chemoradiatio[J].Cancer,2012,118(10):2632-2640.
[8]朱旭勇.三维适形放疗同步化疗治疗中晚期食管癌的疗效与安全性研究[J].中国实用医药,2013,8(05):102-103.
[9] Hishikawa Y,KurisuK,Tanrguchae M,et al.Radiotherapy for carcinoma of the esophagus in patients aged eighty orolder[J].Int J Radiao Oncol Biol Phys,1999,35(7):685-688.
[10]洪英财,陈怀生,林少霖,等.三维适形放疗联合同步化疗治疗食管癌的临床疗效分析[J].实用癌症杂志,2015(12):1927-1930.
[11] Holme RS,Vaughan TL.Epidemiology and pathogenesis of esophageal cancer[J].Semin Radiat Oncol,2007,17(1):2-9.
[12] Sun JF,Wu RR,Norrs C,et al. Safety of chronic low dose capedit abine as maintenance therapy in gastrointestinal cancers[J]. Gastrointest Cancer Res,2009,3(4):134.
[13] Chen J,Hong G,Zhai T, et al. Radiation dose escalation by simultaneous modulated accelerated Jradiotherapy combined with chemotherapy for esophageal cancer:a phaseⅡstudy[J]. Oncotarget,2016,7(16):22711-22719.
[14]蔡宇辉.三维适形放疗联合替吉奥同步化疗治疗老年食管癌疗效观察[J].世界最新医学信息文摘,2017(38):1213-124.
[15]闵贝贝.食管癌放疗后复发再程三维适形放疗同步化疗的临床疗效及安全性分析[J].湖南师范大学学报(医学版),2015,12(05):20-22.
[16]陈庆生,张坤强,曾德豪,等.三维适形放疗联合同步化疗治疗食管癌的疗效观察[J].吉林医学,2014,35(9):1808-1809.
[17] Zhu LL,Yuan L,Wang H,et al. A meta-analysis of concurrent chemo radiotherapy for advanced esophageal cancer[J].Plos One,2015,10(6):616-621.
[18]熊伟民,李明峰,席素娟.三维适形放疗同步化疗对中晚期食管癌患者生存质量影响的临床研究[J].实用癌症杂志,2014,29(12):1553-1555.
[2]张德智,王璐瑶,梁怀虹.中晚期食管癌患者3D-CRT同步化疗的临床效果[J].中国实用医药,2017,12(03):25-27.
[3]沈文斌,高红梅,祝淑钗,等.95例伴气管食管沟淋巴结转移食管癌三维放疗±化疗疗效分析[J].中华放射肿瘤学杂志,2015,24(1):36-40.
[4]张彬,乔田奎,高彩霞,等.同期适形放疗联合化疗治疗中晚期食管癌的临床研究[J].中国癌症杂志,2011,21(10):803-806.
[5]姜威.三维适形放疗同步化疗治疗中晚期食管癌的疗效评价[J].中国继续医学教育,2016,8(19):104-106.
[6]赵维勇,张丽珍,王继荣,等.三维适形放疗联合不同化疗方案治疗中晚期食管癌的临床研究[J].现代肿瘤医学,2012,20(5):956-958.
[7] WelshJ,Settle SH,AminiA,et al.Failure pattems in patients with esophageal cancer treated with definitive chemoradiatio[J].Cancer,2012,118(10):2632-2640.
[8]朱旭勇.三维适形放疗同步化疗治疗中晚期食管癌的疗效与安全性研究[J].中国实用医药,2013,8(05):102-103.
[9] Hishikawa Y,KurisuK,Tanrguchae M,et al.Radiotherapy for carcinoma of the esophagus in patients aged eighty orolder[J].Int J Radiao Oncol Biol Phys,1999,35(7):685-688.
[10]洪英财,陈怀生,林少霖,等.三维适形放疗联合同步化疗治疗食管癌的临床疗效分析[J].实用癌症杂志,2015(12):1927-1930.
[11] Holme RS,Vaughan TL.Epidemiology and pathogenesis of esophageal cancer[J].Semin Radiat Oncol,2007,17(1):2-9.
[12] Sun JF,Wu RR,Norrs C,et al. Safety of chronic low dose capedit abine as maintenance therapy in gastrointestinal cancers[J]. Gastrointest Cancer Res,2009,3(4):134.
[13] Chen J,Hong G,Zhai T, et al. Radiation dose escalation by simultaneous modulated accelerated Jradiotherapy combined with chemotherapy for esophageal cancer:a phaseⅡstudy[J]. Oncotarget,2016,7(16):22711-22719.
[14]蔡宇辉.三维适形放疗联合替吉奥同步化疗治疗老年食管癌疗效观察[J].世界最新医学信息文摘,2017(38):1213-124.
[15]闵贝贝.食管癌放疗后复发再程三维适形放疗同步化疗的临床疗效及安全性分析[J].湖南师范大学学报(医学版),2015,12(05):20-22.
[16]陈庆生,张坤强,曾德豪,等.三维适形放疗联合同步化疗治疗食管癌的疗效观察[J].吉林医学,2014,35(9):1808-1809.
[17] Zhu LL,Yuan L,Wang H,et al. A meta-analysis of concurrent chemo radiotherapy for advanced esophageal cancer[J].Plos One,2015,10(6):616-621.
[18]熊伟民,李明峰,席素娟.三维适形放疗同步化疗对中晚期食管癌患者生存质量影响的临床研究[J].实用癌症杂志,2014,29(12):1553-1555.